Subjects: Statistics >> Social Statistics submitted time 2024-03-27 Cooperative journals: 《中国科学院院刊》
Abstract： In recent years, artificial intelligence (AI) has achieved numerous disruptive breakthroughs in frontier scientific and technological fields, such as AlphaFold2 for protein structure prediction, intelligent control of nuclear fusion, and drug design for COVID-19. These achievements indicate that AI for Science is becoming a new paradigm in research. To achieve fundamental scientific innovation and major technological breakthroughs in the era of intelligence, two core issues should be addressed: 1) how to harness the generality and creativity of the new-generation of AI, especially generative AI and large language models (LLMs), to promote the formation of new paradigms; 2) how to empower and transform traditional scientific facilities using AI. To tackle these challenges, this study proposes a concept of AI-enabled scientific facility (AISF) that caters to the requirements of both establishment of totally new intelligent scientific facility and AI empowerment of existing scientific facilities. It aims to construct an infrastructure system for AI for Science, enabling innovative functionalities such as scientific large language models (LLMs), generative simulation and inversion, autonomous intelligent unmanned experiments, and large-scale trustworthy scientific collaboration. These advancements will accelerate scientific discoveries, synthesis of transformative materials, and application of related engineering technologies.
Subjects: Medicine, Pharmacy >> Clinical Medicine submitted time 2022-12-20 Cooperative journals: 《中国全科医学》
Abstract：
Objective To investigate the occurrence and treatment process of endocrine adverse reactions caused by Immune checkpoint inhibitors (ICIs) in the real world. Methods Patients with solid tumors treated with ICIs in our hospital from January 2019 to March 2022 were retrospectively analyzed. Endocrine system adverse reactions occurred during treatment were observed, and standardized management was conducted according to grade.. Results A total of 204 patients were included, and 12 patients had ICIS-related adverse endocrine reactions. Among them, 9 cases (4.4%) were hypothyroidism (1 case of gradeⅠ, 7 cases of grade Ⅱ, 1 case of grade Ⅲ), and the median onset time was 7 weeks after the first dose of immunological drugs. One case (0.5%) had hyperthyroidism (gradeⅠ), which occurred 9 weeks after the start of immunotherapy. One patient (0.5%) developed type 1 diabetes (grade Ⅳ) 6 weeks after auto-immunotherapy. One patient (0.5%) had grade Ⅲ adrenal dysfunction, which occurred 7 weeks after immunotherapy. All patients were treated in time according to the hierarchical management process, and the symptoms were improved or returned to normal, and ICIs was continued to be given subsequently. Conclusion During the use of ICIS, the risk of adverse reactions in the endocrine system is relatively high, especially the abnormal thyroid function,which requires regular detection of endocrine indicators during treatment. Timely treatment will not affect the subsequent treatment of ICIs.
Subjects: Biology >> Bioengineering submitted time 2018-10-26 Cooperative journals: 《中国生物工程杂志》
Abstract：目的：探讨微环境中钙周期素S100A6 是否通过影响巨噬细胞（macrophages, Mφ）进而促进结直肠癌（colorectal cancer, CRC）细胞的增殖及其机制。方法：制备（原核表达）并鉴定带GST（glutathione S-transferase，谷胱甘肽S-转移酶）标签的人重组S100A6蛋白(recombinant GST-hS100A6，rS100A6) 和对照蛋白GST；采用台盼兰计数、CCK8和结晶紫染色检测CRC细胞系HCT116的增殖能力；用定量实时聚合酶链反应检测Mφ中IL-6 mRNA水平；用Western blot检测Mφ中IL-6的蛋白水平、HCT116细胞中JAK2和STAT3及其磷酸化水平。 结果：（1）成功制备rS100A6和GST蛋白。（2）与经rS100A6处理的Mφ（即A6-Mφ）共培养后，HCT116细胞的增殖能力增强（P<0.05）；同时，HCT116细胞中的JAK2和STAT3水平无明显变化，但其磷酸化水平提高（P<0.05）。（3）A6-Mφ中，IL-6的mRNA和蛋白水平均升高（P<0.05）。（4）在HCT116与A6-Mφ的共培养体系中加入IL-6R封闭肽后，A6-Mφ促HCT116细胞的活力和增殖能力的作用被部分逆转（P<0.05）。 结论：微环境中的S100A6可通过上调巨噬细胞中IL-6的表达、进而激活HCT116细胞中IL-6/JAK2/STAT3信号通路来促进CRC细胞的增殖。
Hits
Hits
Downloads
Comment